Summary: Cerebral muscanmc cholinergic receptors were imaged and regionally quantified in vivo in humans with the use of [IIClscopolamine and positron emission tomography. Previous studies in experimental animals have suggested the utility of radiolabeled scopolamine for in vivo measurements, on the bases of its maintained pharmacologic specificity following systemic administra tion and the exclusion of labeled metabolites from the brain. The present studies describe the cerebral distribu tion kinetics of [llC]scopolamine in normal subjects fol lowing intravenous injection. Scopolamine is initially de livered to brain in a perfusion-directed pattern. After 30 to 60 min, activity is lost preferentially from cerebral structures with low muscarinic receptor density including the cerebellum and thalamus. Activity continues to accu mulate throughout a 2 h postinjection period in receptor rich areas including cerebral cortex and the basal ganglia. The late regional concentration of [llClscopolamine does Neuropathologic knowledge of many neurologic and psychiatric illnesses is limited to postmortem observations of changes in specific neuronal popu lations or neurochemical markers. These markers
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include neurotransmitter receptors, enzymes of neurotransmitter metabolism, or presynaptic neuro transmitter or precursor uptake sites. Although es sential to further understanding of the disease pro cesses, postmortem assays are often confounded by effects of prior drug therapy and chronic illness. In most cases, the pathophysiologic mechanisms un derlying human diseases of the central nervous sys tem are unknown and animal models that accurately reflect the observed changes are lacking. Methods for noninvasive in vivo determination of cerebral biochemistry and pharmacology offer a unique bridge between animal and postmortem clinical ex perimental designs, and may allow direct investiga tion of pathophysiologic hypotheses arising from these observations. Many of the neurodegenerative diseases are char-acterized by selective losses of neuronal popula tions and attendant specific enzymatic and struc tural markers. In other cases, there may be second ary alterations induced by neuronal dysfunction or loss, or by drug therapy (denervation and regula tory changes). As examples, the muscarinic cholin ergic receptor (MAChR) is lost from the striatum during the course of Huntington's disease (Enna et aI. , 1976; Wastek and Yamamura, 1978) . While there is therapeutic evidence for a role of muscarin ic systems underlying idiopathic dystonia (Fahn, 1983) and the tremor in Parkinson's disease, post mortem studies have not indicated a consistent change in cholinergic markers (Ruberg et aJ., 1982) . Recent emphasis has been directed toward devel opment of new positron emission tomography (PET) techniques for determination of neurotrans mitter receptors. These methods will permit deter minations in early symptomatic clinical popula tions, prior to the onset of nonspecific or therapy induced secondary changes, and may thus resolve discrepancies between clinical and postmortem ob servations. Prior studies from our laboratory have described radiotracer methods for in vivo determination of ce rebral MAChRs in experimental animals. We char acterized the in vivo distribution of [N-methyl-3H]scopolamine (eH]scopolamine) in the rat brain utilizing both equilibrium (Frey et al. , 1985a,b) and tracer kinetic (Frey et aJ. , 1985c ) experimental de signs. These studies indicate the suitability of la beled scopolamine for in vivo determination of MAChRs on the basis of several essential tracer properties. Scopolamine enters the brain by passive diffusion from the systemic circulation, and nonspe cific and free ligand pools in tissue are minor in comparison to specifically bound ligand under trace as well as near-total receptor occupancy conditions. Scopolamine maintains in vivo its high in vitro se lectivity for specific binding to the MAChR. No high-affinity binding or other saturable distribution property other than interaction with the muscarinic receptor is identified. In addition, there are no de tectable metabolites of eHlscopolamine in brain that would interfere with external imaging of the ligand distribution in vivo. Significant amounts of volatile 3H-Iabeled materials are produced, presum ably following peripheral demethylation, but the la beled nonvolatile metabolites present in peripheral organs and blood are polar and thus do not cross the blood-brain barrier readily.
In the present work, principles developed in ex perimental animals are extended to the visualization of MAChR binding in human brain with the use of PET. The method employed makes use of the pos- itron-emIttmg ligand [IlC] scopolamine, coupled with dynamic brain imaging and kinetic analysis of cerebral tracer uptake and distribution.
MATERIALS AND METHODS

Synthesis of radiolabeled scopolamine
The synthesis of [N-methyl-llC]scopolamine ([IIC]SCO polamine) has been described in detail previously (Mul holland et aI., 1988b) . Norscopolamine was alkylated with [IIC] formaldehyde in the presence of phosphite at 75 to 80°C. The product was purified by HPLC and specific activity estimated on the basis of the ultraviolet (UV) absorbance of the product peak at 214 nm. Routine radio chemical yields of 20 to 40% (decay corrected to the end of cyclotron bombardment) at specific activities of 350 to 1,300 Ci/mmol are obtained by this method. Custom syn thesis of [N-methyl-3H] 
Radiation dosimetry of [ ll C]scopolamine
The radiation dose to humans from [IIC]scopolamine was estimated from distribution studies in the rat. Ani mals injected intravenously with [IIC] scopolamine were killed at intervals over the following 90 min. Tissue sam ples were dissected, weighed on an analytical balance, and assayed for IIC content in a gamma counter. Human dosimetry estimates were calculated following the Medi cal Internal Radiation Dose formalism (Loevenger and Berman, 1975) .
Human subjects
The biodistribution of [IIC]scopolamine in human brain was investigated in six normal volunteers. Subjects were free of significant medical illness by history and had nor mal general physical and neurologic examinations. There was no recent (within 1 month) history of regular use of centrally acting prescription medications. None of the subjects had consumed nonprescription medications with anticholinergic activity (antihistamines, soporifics, etc.) within the previous week. Written informed consent was obtained for the experimental procedures. The protocol was reviewed and approved by the University Committee on the Use of Human Subjects in Research and by the University Radioactive Drug Research Committee.
Determination of [ ll C]scopolamine distribution in human brain
Following percutaneous radial artery cannulation for withdrawal of blood samples, intravenous cannulation was performed in the contralateral arm. Subjects were studied supine with eyes and ears unoccluded in a dimly lit room. A Cyclotron Corporation TCC PC4600A tomo graph in the wobbled mode (full width at half-maximum within-plane and axial reconstructed resolutions of ap proximately 11 mm) was used to image simultaneously five slices separated by 11.5 mm, beginning inferiorly at 2.4 cm above and parallel to the orbitomeatal line. The scanned field of view thus contained the cerebellum and pons in the most inferior plane and terminated at or above the level of the bodies of the lateral ventricles.
A dynamic sequence of scans was initiated immediately following intravenous bolus injection of [llC]scopolamine and extended over the subsequent 90 to 130 min. Scan acquisition times were 5 x 1,4 x 2.5,3 x 5, and 4 x 10 min followed by 3 x 20 min. Coincident with initiation of the scanning sequence, timed arterial blood samples (1 to 2 ml each) were withdrawn into heparinized syringes. Samples were collected at 10 to 15 s intervals for the first 2 min, followed by additional samples at 3, 4, 5, 7.5, 10, 15,30,45,60,90 , and 130 min postinjection. Plasma was obtained by centrifugation and analyzed as described be low.
Images were reconstructed using elliptical attenuation correction, a Hanning filter (1.0 cycle/cm cutoff), and were corrected for random coincidences, scanner dead time, and isotopic decay of !lC. Brain regions were iden tified from the later images and region-of-interest tem plates were drawn representing major cerebral structures in each hemisphere and within multiple planes. Individual regional time-activity curves were then generated by mapping the templates onto the entire dynamic sequence of images.
Metabolite correction of arterial plasma
A rapid chromatographic method for the separation of labeled metabolites from [!lClscopolamine in arterial plasma was developed and tested with the aid of tritiated metabolites extracted from the liver of a male Sprague Dawley rat. Thirty minutes following the intravenous in jection of 500 ,..., Ci of eHlscopolamine, the rat was killed by decapitation. Samples of plasma and liver were ob tained and frozen at -70°C until use. Metabolites were isolated by homogenization of the liver in 10 volumes of 70% ethanol followed by centrifugation. The supernatant was concentrated by evaporation under vacuum followed by thin-layer chromatography as described previously (Frey et a!., 1985b) . The locations of labeled compounds were determined by contact autoradiography against ra diographic film for 1 week at -70°C with the use of a flu orographic enhancer (Enhance, New England Nuclear, Boston, MA, U.S.A.). Samples of metabolites and au thentic [3Hlscopolamine were then screened for retention on Sep-Pak C I 8 chromatography columns (Waters Div., Millipore Corp., Milford, MA, U.S.A.) with a variety of mobile phase solvents. Labeled compounds in eluted fractions were quantified with the use of liquid scintilla tion spectrometry.
Human arterial plasma samples (250 ,..., 1) were assayed for total activity in a NaI well counter. Additional ali quots were analyzed for metabolites vs. authentic scopol amine by adding 400 ,..., 1 of plasma to tubes containing 100 ,..., 1 of [3Hlscopolamine (0.05 to 0.1 ,..., Ci) in water and 500 ,..., 1 of 40 mM sodium borate buffer (pH 9.5). Samples w � re then applied to Sep-Pak C I 8 columns followed by washmg with 10 ml of 10% acetone:90% 20 mM sodium borate. A purified scopolamine fraction was then eluted in 5 ml of acetone. Both the initial buffer (wash) and the acetone (scop) elutions were collected in 20 ml glass scintillation vials and were assayed for IIC content in the well counter. Following decay of the IIC activity, aliquots were assayed for 3H content with the use of liquid scin tillation spectrometry. The resultant 3H and IIC activities in the wash and scop elutions were used to determine the fraction of total II C activity in the plasma attributable to unmetabolized scopolamine (scopfrac):
The arterial input curve for authentic [IIClscopolamine was then calculated from the scopfrac and the corre sponding total plasma IIC activity:
where t denotes the time postinjection of the arterial sam pling. Chromatography was routinely performed only on plasma samples obtained more than 2 min postinjection, since there was no evidence of ligand metabolism at ear lier times in initial studies.
Analysis of regional brain scopolamine uptake
The PET data were analyzed according to both static and tracer kinetic methods. The whole brain uptake of tracer was estimated from the average activity in all slices at 70 to 90 min, assuming an average brain volume of 1,237 ml (Davis and Wright, 1977) . Static regional brain uptake of scopolamine was determined at 70 to 90 min and was expressed relative to average whole brain activ ity.
Tracer kinetic analysis of scopolamine uptake and binding was performed on the basis of a compartmental model and operational solution developed previously in our laboratories (Frey et a!., 1985c) (Fig. 1) . The model assumes three tracer compartments: intravascular, free plus nonspecifically bound tracer in tissue, and tracer bound to muscarinic receptors. Movement of ligand be tween compartments is described by three first-order rate constants. Dissociation of specifically bound tracer was assumed to be negligible during the imaging period, as predicted from prior animal studies (Frey et a!., 1985c) and verified in initial analysis of the present data with and without a dissociation rate parameter (data not pre sented). The rate constants and their physiologic equiva lents are given below:
b aIDV, DV = K I (l + ks/k6)/k2
where f is cerebral blood flow (ml/g/min), PS is the cap illary permeability-surface area product (mllg/min), DV is the apparent tissue distribution volume of free and non specifically bound tracer relative to arterial plasma (mllg), kon is the bimolecular association rate constant for ligand binding to receptor (ml/mollmin), and [Rl is the concen tration of free receptors (mol/mI). The following relation ship has been previously derived for description of ligand distribution under these conditions (Frey et a!., 1985c) :
where C A (t) and CT(t) represent arterial and total tissue tracer concentrations at time t, respectively, and ® rep resents the convolution operator. The PET measure ments reflect both intravascular and extravascular tracer and are obtained as integrals of brain activity over the scan acquisition interval, necessitating the use of the fol lowing expression:
where PET(I) represents activity in scan I obtained over
[� :J
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Blood-Brain Barrier interval t, to t2 and CBV is the cerebral blood volume (ml/g). Model parameters were estimated using the nonlinear least-squares optimization procedure of Marquardt (1963) with the constraint that the rate parameters could not assume negative values. The variables a, b, c, and CBV were directly estimated from the brain and arterial plasma time-activity curves. The resultant values for k, and DV were then derived according to the relationships given above in Eqs. (4)
-(6).
A constrained fitting procedure was additionally eval uated in receptor-rich brain regions. The algorithm con sisted of determination of DV in the cerebellum as de scribed above [Eqs. (7) and (8) 
RESULTS
Dosimetry estimates for [ ll C)scopolamine
The estimated human dosimetry for e iC]SCOpo lamine indicates that the liver, kidney, testes, and brain receive 0.040, 0.029, 0.028, and 0.005 rad/ mCi, respectively, following systemic administra tion. Activity in the former two organs likely re flects predominant sites of metabolic transforma tion and excretion of the tracer. Other organs receive lower doses, ranging between 0.02 and 0.004 rad/mCi.
Analysis of [ ll C)scopolamine and metabolites in plasma
Initial studies with the use of 3H-Iabeled metab olites from rat liver permitted development of a rapid single-step chromatographic purification of eH]scopolamine. The separation yielded better than 95% exclusion of the major metabolites ex tracted from rat plasma with 85% retention of sco polamine on the column during the initial wash, and essentially complete recovery of activity applied to the column. Analysis of plasma samples from the human studies revealed that essentially all of the activity immediately following injection was ac counted for by e iC]scopolamine. Within 3 to 5 min postinjection, radiolabeled metabolites appeared in increasing relative proportion, and accounted for over 85% of plasma activity by 90 min postinjection (Fig. 2) .
Uptake and distribution of [ ll C)scopolamine in human brain
Six normal volunteers between the ages of 20 and 60 years were studied (Table 1) . Imaging doses be tween 21 and 40 mCi were administered, and all resulted in high-quality emission data with distinct visualization of the brain and major neuroanatomic structures during the scanning session. Whole brain uptake 70 to 90 min postinjection averaged 3.2% of the administered dose, resulting in an estimated av erage brain concentration of 2.6 nM. There were no systemic pharmacologic effects of scopolamine ob served at these dosages in any of the subjects, and none reported symptoms of sedation, blurring of vision, or difficulty with memory.
The pattern of uptake and retention of [llC]SCO polamine was qualitatively similar in each of the subjects (Figs. 3 and 4) . Initial images demonstrated prominent intravascular activity, with distinction of major cerebral blood vessels and venous sinuses. Over the first 10 min postinjection, significant brain parenchymal tracer uptake was observed in a pat tern resembling cerebral perfusion. Distinction of white and gray matter structures was evident at these times, without clear differentiation between gray matter structures possessing high (basal gan glia, cerebral cortex) vs. low (cerebellum) musca rinic receptor concentrations. By 30 min postinjec- Time Post-Injection (min)
tion, and continuing throughout the remainder of the experiment, tracer retention in regions with moderate to high receptor concentrations in creased, while activity began to clear from the cer ebellum. Regional analysis of the delayed uptake at 70 to 90 min postinjection revealed over twofold differences between scopolamine accumulation in the occipital cortex vs. the cerebellum. The delayed distribution alone did not, however, distinguish the known higher receptor concentration in the stria tum from neocortical regions, or that in the cortex from the thalamus. In addition to cerebral and vas cular structures, the pituitary was transiently dis tinguished between 5 and 15 min postinjection and persistent activity in the region of the lacrimal glands was apparent after the first 5 min of imaging.
Compartmental analysis of [ ll C]scopolamine distribution
Tracer kinetic analysis of regional brain e lC]SCO pol amine uptake and retention was initially carried out with the use of Eqs. (7) and (8), resulting in estimates of three parameters (Table 2) . In some instances, the curve-fitting algorithm failed to con verge or the resulting parameter estimates fell out side of reasonable physiologic ranges (k3 less than Values for the blood-to-brain transport rate con stant K 1 ranged from 0.09 to 0.12 across the gray matter regions studied, and were consistent across individuals. In the cerebellum, the best-fit values for DV and k3 were again consistent across individ uals, and were in keeping with results of previous studies in experimental animals. The estimates of DV and of k3 in other gray matter regions, however, varied over 5-to 10-fold ranges across individuals. There was also considerable variability between multiple samples of the same regions within individ uals.
As a result of the above difficulties in simulta neously estimating three kinetic rate constants in receptor-rich brain regions, a constrained curve fitting procedure was applied. Results of fitting with DV fixed to the value estimated in the cerebellum revealed essentially unchanged estimates of K 1 (data not shown) and improved consistency of k3 values. Further reduction in variability was achieved by expression of regional k3 relative to cerebellar k3 (Table 2) . Regional estimates of recep tor binding by these latter methods reveal a 30-fold range across the brain regions examined. Relative differences in specific binding between cerebellum, thalamus, neocortex, and the caudate nucleus are evident, and are in good agreement with results of previous in vitro receptor assays (Lin et aI., 1986; Cortes et aI. , 1987) . roughly parallels in vitro measures of muscarinic receptor density, with the highest retention in the basal ganglia and cerebral cortex, and lowest gray matter values in the cerebellum. However, the de layed distribution data alone do not permit distinc tion of known receptor concentration differences between the striatum, the cerebral cortex, and the thalamus. Furthermore, the cortical and cerebellar labeling differ by less than 2.S-fold while in vitro measures predict a 30-fold difference, indicating the effect of other factors on in vivo scopolamine dis tribution.
Prior results obtained in the rat indicated the value of kinetic ligand distribution analysis to iso late estimates of receptor binding from effects of
�) e C Parameter estimates resulting from the use of Eqs. (4)- (8) with the DV fixed to the value from the cerebellum.
d Regional k3 values expressed relative to the cerebellum.
e In vitro equilibrium eHJQNB binding (Lin et al. 1986) , expressed relative to the cerebellum. The constrained fitting procedure overcomes this limitation, but depends on the accuracy of the as sumed tissue DV. Thus, errors in the determination of the arterial input function as well as in the cere bellar kinetic fit used for DV estimation both con tribute to inaccuracy of the constrained estimates of receptor binding. Effects of these global sources of error may account for the observed improvement in precision when binding is expressed relative to the cerebellum. Validity of the current kinetic analysis relies on the acquisition of authentic tracer time-activity curves for both the arterial plasma and for brain regions of interest. Prior studies indicate the ab sence of nonvolatile labeled scopolamine metabo lites in brain following administration of [N-methyl-3H]scopolamine in the rat (Frey et aI., 1985a) . We therefore interpret cerebral activity following ad ministration of [N-methyl-llC]scopolamine in the human as unmetabolized tracer. Prior animal stud ies as well as the present human studies, however, reveal the presence of extensive peripheral conver sion of labeled scopolamine to polar metabolites that do not readily cross the intact blood-brain bar rier. In plasma, scopolamine metabolites are detect able within 3 to 5 min following i. v. injection, and account for >80% of the activity by 45 min postin jection. Thus, the present analysis is critically de pendent on the correction of arterial plasma tracer activity for the presence of labeled metabolites.
As a result of the need for metabolite correction mentioned above, we developed a novel method for rapid column chromatography of plasma samples that is capable of processing more than 20 discrete samples within the time constraints imposed by the 20 min isotopic half-life of \lC. The method is based on the use of a tritiated internal standard to correct for loss of ligand during the separation process. As a result, accurate, one-step chromatographic sepa rations are achievable with the use of commercially available disposable chromatography columns. The stringent conditions of purity result in significant loss of authentic scopolamine into the metabolite fraction; however, this is quantified and corrected on the basis of the internal standard. We have sub sequently improved the method to include verifica tion of the purity of the tritiated standard with each use by chromatographing a sample of the [\lC]li gand prior to injection. In this instance, the calcu lated purity of the \lC-labeled ligand should agree with analytic HPLC performed during radiochem istry quality control. If the calculated purity signif icantly exceeds this value, impurity in the tritiated standard is indicated. This double-label chromato-graphic approach is not limited to the study of sco polamine, and may be modified with appropriate selection of stationary and mobile phases for quan tification of radiolabeled metabolites in a variety of in vivo radiotracer applications. The strength of the method lies in the rapidity of sample processing, maximizing its utility with the use of short-lived ra dioisotopes. We have subsequently employed this approach in studies following in vivo administration of e1C]tropanyl benzilate (Frey et aI., 1990) and of [llC]flumazenil (Koeppe et aI., 1991) .
The present studies demonstrate the feasibility of in vivo muscarinic receptor imaging in human brain. Comparable brain images have been reported from other laboratories with the use of e 1 C]benztropine ([llC]BZT) (Dewey et aI., 1990) (Eckelman et aI., 1984; Holman et aI., 1985) . As in the present work, both of these ligands reveal distinction between cerebral cortical and cerebellar activities following systemic injection. However, as seen with [llC]SCO polamine, the distributions of these ligands within 1 to 2 h postinjection also fail to demonstrate the dy namic range of regional brain receptor concentra tions anticipated on the basis of in vitro studies. Thus, it is likely that the distributions of [123I]IQNB and e lC]BZT are also influenced by ligand trans port in addition to local receptor availability. A re cent kinetic analysis of IQNB distribution in the rat confirms this hypothesis (Sawada et aI., 1990) .
In summary, we present evidence that compart mental modeling and tracer kinetic analysis of [llC]scopolamine distribution may be applied to measurement of regional cerebral muscarinic recep tors in the living human brain. The results obtained are in good agreement with expectations on the ba sis of in vitro studies; however, the limited preci sion of the method may preclude its widespread use in clinical research protocols. Further studies are in progress to evaluate the use of alternative musca rinic ligands (Mulholland et aI., 1988a; Frey et aI., 1990) according to the general experimental design developed and presented here.
